Obesity treatment stock, Viking Therapeutics (SYM: VKTX) is still attractive.
While it already ran from about $5 to a high of $99.41, it’s recent pullback to $52.73 is interesting. All thanks to its experimental weight loss treatment, VK2735, a peptide GLP-1/GIP dual agonist in trials for injections and oral dosages.
Helping, Goldman Sachs just raised its obesity drug market estimate to $130 billion from $100 billion. All on the belief that about 19 million Americans could be on anti-obesity drugs by 2030, up from a prior estimate of 15 million.
Even better, Viking is turning heads with its potential treatment for non-alcoholic steatohepatitis, or NASH. In a recent Phase 2b VOYAGE study of its VK2809 treatment in patients with biopsy-confirmed non-alcoholic steatohepatitis, the company “achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo.”
Both treatments for NASH and obesity could send VKTX screaming to higher highs.
